This activity is intended for primary care physicians, diabetologists and endocrinologists, nurses, and nurse practitioners.
The goal of this activity is to improve use of integrated continuous glucose monitoring (iCGM) in patients with type 2 diabetes (T2D).
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 3/26/2021; Reviewed and Renewed: 4/14/2022
Valid for credit through: 4/14/2023, 11:59 PM EST
processing....
Editor’s Note: The US FDA on February 11, 2022, approved the Eversense implantable continuous glucose monitoring (CGM) system for use up to 6 months/180 days in adults with diabetes. Two fingerstick blood glucose measurements are only required for the first 21 days for calibration; after day 21, only 1 fingerstick is needed. On June 3, 2021, the Centers for Medicare and Medicaid Services eliminated the requirement of the ≥ 4 times per day fingerstick testing for patients with type 1 diabetes and type 2 diabetes on insulin to qualify for coverage of a CGM. This coverage change for therapeutic CGMs took effect on July 18, 2021. Medicare beneficiaries now also have access to any CGM system by any supplier enrolled as a durable medical equipment supplier, including pharmacies.
The goal of this activity is to improve use of integrated continuous glucose monitoring (iCGM) in patients with type 2 diabetes (T2D).
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.